Novartis pelacarsen fails late-stage cholesterol study

Novartis AG (NVS, Financials) received a setback after its experimental cholesterol drug pelacarsen failed in a high-profile late-stage study. The result underscores the risk to prospective medicine sales for a programme that had been seen as a significant commercial opportunity.